background
inappropri
use
antibiot
increas
resist
reduc
effect
despit
evidencebas
guidelin
antibiot
still
commonli
use
treat
infect
like
caus
respiratori
virus
studi
examin
tempor
relationship
antibiot
usag
respiratori
infect
republ
korea
method
number
monthli
antibiot
prescript
incid
acut
respiratori
tract
infect
primari
care
clinic
obtain
korean
health
insur
review
assess
servic
monthli
detect
rate
respiratori
virus
includ
adenoviru
respiratori
syncyti
viru
influenza
viru
human
coronaviru
human
rhinoviru
collect
korea
center
diseas
control
prevent
crosscorrel
analysi
conduct
quantifi
tempor
relationship
antibiot
use
respiratori
viru
activ
well
respiratori
infect
primari
clinic
result
monthli
use
differ
class
antibiot
includ
penicillin
betalactam
antibacteri
macrolid
quinolon
significantli
correl
influenza
viru
activ
correl
peak
lag
crosscorrel
coeffici
p
p
p
respect
furthermor
signific
correl
found
acut
bronchiti
antibiot
includ
penicillin
p
macrolid
p
quinolon
p
lag
conclus
find
suggest
signific
tempor
relationship
influenza
viru
activ
antibiot
use
primari
clinic
relationship
indic
intervent
aim
reduc
influenza
case
addit
effort
discourag
prescript
antibiot
physician
may
help
decreas
unnecessari
antibiot
consumpt
overus
inappropri
use
antibiot
drive
emerg
spread
antimicrobi
resist
republ
korea
number
antibiot
prescript
rel
higher
defin
daili
dose
ddd
per
inhabit
per
day
member
countri
organ
econom
cooper
develop
mean
ddd
per
inhabit
per
day
korea
major
antibiot
ca
prescrib
primari
care
mainli
acut
respiratori
tract
infect
arti
ca
arti
mainli
viral
origin
gener
selflimit
requir
antibiot
secondari
bacteri
pneumonia
import
clinic
complic
respiratori
viral
infect
howev
previou
studi
shown
antibiot
improv
outcom
patient
arti
prevent
overus
inappropri
use
antibiot
essenti
identifi
understand
antibiot
prescrib
pattern
determin
factor
howev
littl
known
antibiot
prescrib
pattern
republ
korea
purpos
studi
describ
antibiot
prescript
pattern
primari
care
clinic
period
identifi
tempor
relationship
respiratori
virus
arti
nation
health
insur
cover
total
korean
popul
provid
nearcomplet
coverag
antibiot
prescript
republ
korea
reimburs
data
healthcar
servic
provid
korea
collect
korean
health
insur
review
assess
servic
khira
data
cover
million
patient
annual
approxim
popul
republ
korea
includ
patient
diagnos
record
use
intern
classif
diseas
clinic
modif
revis
prescript
drug
collect
monthli
antibiot
prescript
data
primari
care
clinic
januari
decemb
accord
anatom
therapeut
chemic
classif
system
tetracyclin
betalactam
antibacteri
penicillin
betalactam
antibacteri
cephalosporin
monobactam
carbapenem
macrolid
lincosamid
streptogramin
aminoglycosid
fluoroquinolon
prescript
data
convert
ddd
per
inhabit
per
day
assum
averag
mainten
dose
per
day
prescrib
medic
popul
data
obtain
censu
data
provid
korean
statist
inform
servic
number
acut
respiratori
viru
diagnos
collect
korea
influenza
respiratori
viru
surveil
system
kinress
korea
center
diseas
control
prevent
kinress
collect
nasopharyng
specimen
patient
acut
respiratori
symptom
includ
cough
rhinorrhea
sore
throat
sentinel
primari
care
clinic
weekli
laboratorybas
surveil
system
oper
sinc
measur
respiratori
viru
activ
commun
level
includ
adenoviru
adv
influenza
viru
ifv
b
human
coronaviru
hcov
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
b
laboratori
confirm
respiratori
pathogen
perform
use
multiplex
polymeras
chain
reaction
pcr
realtim
revers
transcript
pcr
obtain
monthli
number
arti
diagnos
khira
databas
use
code
patient
diagnos
arti
regardless
age
gender
includ
arti
defin
acut
bronchiti
acut
upper
respiratori
tract
infect
addit
includ
acut
tonsil
pneumonia
compar
like
requir
antibiot
arti
incid
calcul
divid
number
arti
diagnos
popul
republ
korea
studi
period
use
regress
analysi
describ
trend
antibiot
use
respiratori
viru
activ
incid
arti
includ
acut
bronchiti
overal
identifi
tempor
relationship
antibiot
prescript
respiratori
viru
activ
incid
arti
perform
crosscorrel
function
test
crosscorrel
test
wide
use
identifi
time
lag
onetim
seri
respiratori
viru
possibl
predictor
anoth
time
seri
antibiot
use
boxjenkin
method
appli
fit
timeseri
data
season
autoregress
move
averag
model
stationari
time
seri
evalu
use
augment
dickeyful
test
determin
whether
differenc
requir
rule
spuriou
correl
akaik
inform
criterion
test
portmanteau
test
normal
check
residu
conduct
identifi
best
model
fit
crosscorrel
analysi
use
residu
timeseri
model
use
evalu
tempor
relationship
antibiot
prescript
rate
respiratori
viru
detect
well
incid
arti
statist
packag
r
version
r
foundat
statist
comput
vienna
austria
use
statist
analysi
pvalu
consid
signific
p
averag
total
antibiot
prescript
studi
period
rang
primari
clinic
prescrib
rate
rang
rang
tendenc
increas
p
fig
commonli
use
class
antibiot
penicillin
rang
mean
betalactam
antibacteri
rang
mean
macrolid
rang
mean
fluoroquinolon
rang
mean
tetracyclin
rang
mean
aminoglycosid
rang
mean
fig
mean
annual
detect
rate
respiratori
virus
fluctuat
highli
larg
stabl
year
though
estim
rang
rel
larg
rang
isol
viru
rang
detect
fig
commonli
detect
respiratori
virus
hrv
rang
median
ifv
rang
median
adv
rang
median
rsv
rang
median
hcov
rang
median
fig
annual
incid
acut
bronchiti
increas
significantli
rang
mean
per
individu
rang
mean
per
individu
p
fig
averag
incid
acut
bronchiti
acut
tonsil
acut
upper
respiratori
tract
infect
pneumonia
per
individu
respect
fig
b
monthli
time
seri
antibiot
use
respiratori
viru
detect
incid
arti
present
fig
season
antibiot
use
clearli
follow
similar
oscillatori
pattern
influenza
viru
detect
antibiot
use
also
similar
season
pattern
incid
acut
bronchiti
acut
upper
respiratori
tract
infect
acut
tonsil
total
monthli
rate
antibiot
prescript
highli
crosscorrel
monthli
detect
rate
influenza
viru
crosscorrel
coeffici
p
bivari
analys
antibiot
use
rate
commonli
use
antibiot
penicillin
betalactam
antibacteri
macrolid
fluoroquinolon
significantli
crosscorrel
influenza
viru
detect
lag
crosscorrel
coeffici
p
p
p
respect
tabl
howev
crosscorrel
found
antibiot
class
lowerus
rate
influenza
viru
detect
rate
signific
crosscorrel
hrv
tetracyclin
lag
crosscorrel
coeffici
p
arti
correl
coefficienct
antibiot
use
incid
acut
bronchiti
p
penicillin
p
betalactam
antibacteri
p
macrolid
p
fluoroquinolon
tabl
acut
upper
respiratori
infect
significantli
correl
penicillin
p
betalactam
antibacteri
p
macrolid
p
fluoroquinolon
p
without
lag
crosscorrel
found
class
antibiot
lowerus
rate
arti
compar
like
requir
antibiot
arti
pneumonia
significantli
correl
penicillin
p
macrolid
p
aminoglycosid
p
betalactam
antibacteri
p
without
lag
furthermor
acut
tonsil
significantli
correl
penicillin
p
betalactam
antibacteri
p
macrolid
p
fluoroquinolon
p
without
lag
studi
first
identifi
tempor
relationship
number
monthli
antibiot
prescript
detect
rate
respiratori
virus
arti
republ
korea
result
suggest
season
variat
number
commonli
prescrib
antibiot
penicillin
betalactam
antibacteri
macrolid
fluoroquinolon
significantli
associ
chang
activ
influenza
commun
season
variat
antibiot
prescript
document
unit
state
canada
europ
furthermor
also
shown
incid
influenza
highli
correl
season
pattern
antibiot
prescript
chang
test
affect
prescript
rate
antibiot
previou
find
support
result
season
antibiot
use
significantli
associ
influenza
viru
activ
countri
asid
correl
hrv
tetracyclin
virus
significantli
correl
antibiot
use
may
due
low
number
antibiot
use
hrv
regard
crosscorrel
influenza
viru
activ
incid
pneumonia
signific
tempor
relationship
found
within
lag
p
like
low
incid
pneumonia
case
per
person
surpris
pneumonia
uncommon
diagnosi
outpati
set
compar
acut
bronchiti
case
per
person
pneumonia
quit
sever
infect
often
requir
hospit
confirm
thu
mani
acut
bronchiti
prescript
might
reflect
uncertainti
clinician
part
whether
patient
may
pneumonia
prescrib
abund
caution
despit
potenti
downsid
consequ
unnecessari
antibiot
use
regard
relationship
influenza
viru
activ
incid
acut
tonsil
signific
crosscorrel
found
p
lag
result
consist
previou
literatur
document
common
caus
tonsil
viral
infect
includ
influenza
viru
conserv
manag
main
treatment
option
patient
tonsil
except
case
streptococc
infect
detect
rate
korea
result
demonstr
antibiot
use
significantli
correl
acut
tonsil
larger
magnitud
influenza
viru
activ
correl
like
result
physician
anxieti
potenti
risk
develop
secondari
bacteri
infect
antibiot
prescrib
respiratori
virus
posit
associ
poor
qualiti
prescrib
patient
satisfact
shown
major
driver
well
even
patient
receiv
delay
antibiot
prescript
less
like
satisfi
treatment
immedi
receiv
prescript
even
treatment
outcom
differ
underli
situat
may
contribut
high
rate
antibiot
use
diagnos
gener
requir
antibiot
result
suggest
antibiot
use
could
lower
reduc
influenza
transmiss
educ
campaign
aim
public
physician
discourag
inappropri
prescrib
antibiot
particularli
influenza
season
moreov
increas
vaccin
coverag
cover
approxim
korean
popul
may
reduc
unnecessari
antibiot
use
improv
pointofcar
test
detect
influenza
viru
may
also
like
reduc
antibiot
use
find
subject
sever
limit
first
studi
ecolog
util
populationlevel
data
thu
may
repres
associ
individu
level
nonetheless
signific
relationship
overus
antibiot
influenza
viru
circul
also
observ
previou
cohort
studi
second
sinc
enteroviru
mean
detect
rate
assess
kinress
sinc
mean
detect
rate
respiratori
virus
human
metapneumoviru
hmpv
human
bocaviru
hbov
human
parainfluenza
viru
hpiv
rel
low
hmpv
hbov
hpiv
virus
consid
studi
third
use
primari
care
clinicbas
sentinel
surveil
data
respiratori
viru
detect
data
could
underestim
strength
viru
activ
howev
pattern
influenza
viru
activ
similar
pattern
influenzalikeil
countri
fourth
number
sampl
collect
consist
year
year
due
variat
respiratori
viru
activ
yearli
mean
number
sampl
collect
fifth
arti
may
includ
infecti
diseas
requir
antibiot
treatment
bacteri
pneumonia
studi
identifi
strong
tempor
associ
antibiot
use
influenza
viru
activ
incid
arti
detect
signific
correl
antibiot
use
common
antibiot
penicillin
betalactam
antibacteri
macrolid
fluoroquinolon
influenza
viru
activ
well
incid
acut
bronchiti
acut
upper
respiratori
tract
infect
result
indic
intervent
aim
reduc
influenza
infect
discourag
use
antibiot
physician
public
may
help
decreas
antibiot
consumpt
addit
studi
includ
precis
evalu
korean
influenza
nation
immun
program
antibiot
prescript
pattern
may
identifi
addit
opportun
reduc
antibiot
prescript
